Insight Molecular Diagnostics Debt to Equity Ratio 2014-2025 | IMDX
Current and historical debt to equity ratio values for Insight Molecular Diagnostics (IMDX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Insight Molecular Diagnostics debt/equity for the three months ending March 31, 2025 was 0.20.
| Insight Molecular Diagnostics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.05B | $0.01B | 4.91 |
| 2024-12-31 | $0.05B | $-0.01B | -3.86 |
| 2024-09-30 | $0.06B | $0.01B | 6.23 |
| 2024-06-30 | $0.05B | $0.02B | 2.29 |
| 2024-03-31 | $0.06B | $0.01B | 5.13 |
| 2023-12-31 | $0.05B | $0.02B | 2.66 |
| 2023-09-30 | $0.04B | $0.04B | 1.17 |
| 2023-06-30 | $0.04B | $0.04B | 1.01 |
| 2023-03-31 | $0.05B | $0.04B | 1.18 |
| 2022-12-31 | $0.07B | $0.03B | 1.92 |
| 2022-09-30 | $0.08B | $0.08B | 1.05 |
| 2022-06-30 | $0.09B | $0.08B | 1.06 |
| 2022-03-31 | $0.09B | $0.06B | 1.57 |
| 2021-12-31 | $0.09B | $0.07B | 1.45 |
| 2021-09-30 | $0.07B | $0.10B | 0.69 |
| 2021-06-30 | $0.08B | $0.10B | 0.73 |
| 2021-03-31 | $0.02B | $0.11B | 0.21 |
| 2020-12-31 | $0.02B | $0.03B | 0.66 |
| 2020-09-30 | $0.02B | $0.04B | 0.67 |
| 2020-06-30 | $0.02B | $0.04B | 0.60 |
| 2020-03-31 | $0.02B | $0.04B | 0.63 |
| 2019-12-31 | $0.01B | $0.03B | 0.29 |
| 2019-09-30 | $0.00B | $0.03B | 0.12 |
| 2019-06-30 | $0.00B | $0.03B | 0.12 |
| 2019-03-31 | $0.00B | $0.04B | 0.09 |
| 2018-12-31 | $0.01B | $0.00B | 1.78 |
| 2018-09-30 | $0.01B | $0.01B | 0.72 |
| 2018-06-30 | $0.01B | $0.01B | 0.78 |
| 2018-03-31 | $0.01B | $0.01B | 0.73 |
| 2017-12-31 | $0.01B | $0.00B | 1.32 |
| 2017-09-30 | $0.01B | $0.01B | 0.77 |
| 2017-06-30 | $0.01B | $0.01B | 1.15 |
| 2017-03-31 | $0.01B | $0.01B | 0.73 |
| 2016-12-31 | $0.01B | $0.01B | 0.47 |
| 2016-09-30 | $0.00B | $0.01B | 0.33 |
| 2016-06-30 | $0.00B | $0.00B | 0.66 |
| 2016-03-31 | $0.00B | $0.01B | 0.40 |
| 2015-12-31 | $0.00B | $0.01B | 0.22 |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2015-03-31 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.01B | $0.00B | -5.90 |
| 2013-12-31 | $0.01B | $0.00B | 1.29 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.080B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.644B | 58.07 |
| Doximity (DOCS) | United States | $11.655B | 53.96 |
| Hims & Hers Health (HIMS) | United States | $11.295B | 117.35 |
| Tempus AI (TEM) | United States | $9.675B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.275B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.775B | 58.99 |
| Hinge Health (HNGE) | United States | $3.572B | 0.00 |
| Privia Health (PRVA) | United States | $2.516B | 172.00 |
| Enovis (ENOV) | United States | $1.765B | 9.84 |
| Phreesia (PHR) | United States | $1.591B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.517B | 0.00 |
| 10x Genomics (TXG) | United States | $1.505B | 0.00 |
| Schrodinger (SDGR) | United States | $1.495B | 0.00 |
| Azenta (AZTA) | United States | $1.461B | 67.89 |
| Evolent Health (EVH) | United States | $1.335B | 113.70 |
| Omnicell (OMCL) | United States | $1.276B | 22.51 |
| Claritev (CTEV) | United States | $0.717B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.550B | 0.00 |
| Veradigm (MDRX) | United States | $0.536B | 0.00 |
| Standard BioTools (LAB) | United States | $0.463B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.435B | 0.00 |
| Talkspace (TALK) | United States | $0.420B | 125.50 |
| TruBridge (TBRG) | United States | $0.321B | 713.00 |
| Outset Medical (OM) | United States | $0.320B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.270B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.260B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.231B | 0.00 |
| CapsoVision (CV) | United States | $0.213B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.203B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.136B | 0.00 |
| American Well (AMWL) | United States | $0.125B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.120B | 0.00 |
| Pulmonx (LUNG) | United States | $0.109B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.103B | 0.00 |
| CareCloud (CCLD) | United States | $0.098B | 3.73 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.083B | 0.00 |
| 111 (YI) | China | $0.064B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.046B | 0.00 |
| HeartBeam (BEAT) | United States | $0.042B | 0.00 |
| Zhongchao (ZCMD) | China | $0.028B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.022B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |